Host genetic polymorphisms in human immunodeficiency virus–related neurologic disease

2004 ◽  
Vol 10 (s1) ◽  
pp. 67-73 ◽  
Author(s):  
Ramon Diaz-Arrastia ◽  
Yunhua Gong ◽  
Cynthia J Kelly ◽  
Benjamin B Gelman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Genetic Polymorphisms ◽  
Neurologic Disease ◽  
Immunodeficiency Virus ◽  
Host Genetic

Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease

2004 ◽  
Vol 10 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Ramon Diaz-Arrastia ◽  
Yunhua Gong ◽  
Cynthia Kelly ◽  
Benjamin Gelman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Genetic Polymorphisms ◽  
Neurologic Disease ◽  
Immunodeficiency Virus ◽  
Host Genetic

Host genetic polymorphisms in human immunodeficiency virus?related neurologic disease

2004 ◽  
Vol 10 (0) ◽  
pp. 67-73 ◽  
Author(s):  
Ramon Diaz-Arrastia ◽  
Yunhua Gong ◽  
Cynthia Kelly ◽  
Benjamin Gelman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Genetic Polymorphisms ◽  
Neurologic Disease ◽  
Immunodeficiency Virus ◽  
Host Genetic

scholarly journals Synonymous Genetic Polymorphisms within Brazilian Human Immunodeficiency Virus Type 1 Subtypes May Influence Mutational Routes to Drug Resistance

2004 ◽  
Vol 189 (7) ◽  
pp. 1232-1238 ◽  
Author(s):  
Ana T. Dumans ◽  
Marcelo A. Soares ◽  
Elizabeth S. Machado ◽  
Stéphane Hué ◽  
Rodrigo M. Brindeiro ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Genetic Polymorphisms ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus

scholarly journals Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Hongshuo Song ◽  
Meera Bose ◽  
Suteeraporn Pinyakorn ◽  
Eric Sanders-Buell ◽  
Anne Marie O’Sullivan ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Human Immunodeficiency Virus ◽  
Acute Infection ◽  
Viral Dynamics ◽  
Virus Envelope ◽  
Acute Infections ◽  
Human Immunodeficiency Virus Envelope ◽  
Immunodeficiency Virus ◽  
Host Genetic ◽  
Human Immunodeficiency Virus 1

Abstract We analyzed human immunodeficiency virus envelope diversity in 98 acute infections. The within-host genetic diversity, divergence from transmitted/founder (T/F) strain, and the observed frequency of multiple T/F infections increased with Fiebig stage. These data identify rapid viral dynamics during acute infection with implications for clinical trials conducted in this setting.

scholarly journals The Roles of Genetic Polymorphisms and Human Immunodeficiency Virus Infection in Lipid Metabolism

2013 ◽  
Vol 2013 ◽  
pp. 1-15 ◽  
Author(s):  
Elaine Regina Delicato de Almeida ◽  
Edna Maria Vissoci Reiche ◽  
Ana Paula Kallaur ◽  
Tamires Flauzino ◽  
Maria Angelica Ehara Watanabe
Keyword(s):  
Human Immunodeficiency Virus ◽  
Lipid Metabolism ◽  
Antiretroviral Therapy ◽  
Lipid Profile ◽  
Genetic Polymorphisms ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active ◽  
Increased Risk ◽  
Immunodeficiency Virus ◽  
Hiv 1

Dyslipidemia has been frequently observed among individuals infected with human immunodeficiency virus type 1 (HIV-1), and factors related to HIV-1, the host, and antiretroviral therapy (ART) are involved in this phenomenon. This study reviews the roles of genetic polymorphisms, HIV-1 infection, and highly active antiretroviral therapy (HAART) in lipid metabolism. Lipid abnormalities can vary according to the HAART regimen, such as those with protease inhibitors (PIs). However, genetic factors may also be involved in dyslipidemia because not all patients receiving the same HAART regimen and with comparable demographic, virological, and immunological characteristics develop variations in the lipid profile. Polymorphisms in a large number of genes are involved in the synthesis of structural proteins, and enzymes related to lipid metabolism account for variations in the lipid profile of each individual. As some genetic polymorphisms may cause dyslipidemia, these allele variants should be investigated in HIV-1-infected patients to identify individuals with an increased risk of developing dyslipidemia during treatment with HAART, particularly during therapy with PIs. This knowledge may guide individualized treatment decisions and lead to the development of new therapeutic targets for the treatment of dyslipidemia in these patients.

Sign in / Sign up

Export Citation Format

Share Document